X4 Pharmaceuticals Q2 EPS $(0.33) Misses $(0.16) Estimate
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals reported Q2 losses of $0.33 per share, missing the analyst consensus estimate of $0.16 by 106.25%. This is a 45% increase over losses from the same period last year.
August 10, 2023 | 10:05 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
X4 Pharmaceuticals reported larger than expected losses for Q2, which could negatively impact investor sentiment.
X4 Pharmaceuticals reported a larger than expected loss for Q2, missing analyst estimates by a significant margin. This could lead to a negative reaction from the market, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100